查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951808

核子医学市场分析及预测（至2035年）：类型、产品类型、服务、技术、应用、最终用户、设备、流程、模式、安装类型

Nuclear Medicine Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Process, Mode, Installation Type
出版日期: | 出版商: Global Insight Services | 英文 332 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计核医市场规模将从2024年的173亿美元成长到2034年的494亿美元，复合年增长率约为11.8%。核子医学市场涵盖使用放射性物质的诊断和治疗应用，包括放射性药物、影像设备以及利用原子核特性进行精准医疗的服务。市场成长的驱动力包括影像技术的进步、慢性病发病率的上升以及对非侵入性诊断技术日益增长的需求。标靶放射性核素治疗的创新和监管核准正在推动市场进一步成长，为改善患者预后和製定个人化治疗策略提供了机会。

核子医学市场正经历强劲成长，这主要得益于诊断成像技术和标靶治疗技术的进步。诊断领域成长最为迅猛，主要得益于SPECT和PET成像技术的日益普及。这些影像方式对于精准的疾病诊断和治疗方案製定至关重要。治疗领域紧随其后，用于肿瘤治疗的放射性药物因其定向和疗效而备受关注。在诊断领域，PET成像有望凭藉主导地位。 SPECT成像凭藉其成本效益和广泛的应用，继续保持第二大细分市场的强劲表现。在治疗领域，针对前列腺癌和神经内分泌肿瘤的放射性药物有望成为未来成长的主要驱动力，这反映了个人化医疗的进步。此外，人工智慧在核子医学领域的应用有望提高诊断准确性和营运效率，从而进一步推动市场扩张。

市场区隔
类型 用于诊断和治疗
产品 放射性药物、核子医学设备
服务 放射性同位素生产、迴旋加速器服务、放射性药物製备、咨询服务
科技 PET、SPECT、α发射体、β发射体、γ发射体
应用领域 肿瘤科、心臟科、神经科、内分泌科、消化科、整形外科
最终用户 医院、诊断中心、实验室
装置 PET扫描器、SPECT扫描器、伽马摄影机
过程 影像诊断、治疗
模式 体内、体外
安装类型 固定式，移动式

核子医学市场正经历显着的发展，这主要得益于竞争格局的加剧以及各种新产品的推出。定价策略和创新产品的推出正日益影响市场份额，重塑消费者的偏好，并推动市场需求。随着各公司致力于提升核医学技术的有效性和准确性，预计市场将实现显着成长。主要企业正策略性地部署其产品，以抓住新的机会，尤其是在医疗保健投资较高的地区。核子医学领域的竞争异常激烈，主要企业积极将自身产品与竞争对手的产品进行比较，以保持竞争优势。监管具有重要影响，北美和欧洲的严格指导方针塑造了营运标准。这些监管规定与技术进步相结合，对市场动态的形成至关重要。该行业的特点是创新与合规之间的密切互动，推动着市场的发展演变。不断完善的法规结构为寻求利用最尖端科技的市场参与企业带来了挑战和机会。

主要趋势和驱动因素：

核子医学市场正经历强劲成长，这主要得益于诊断影像技术和治疗应用的进步。人工智慧（AI）与影像技术的融合是关键趋势，它提高了疾病检测和治疗方案製定的准确性和效率。新型放射性药物的研发拓展了核子医学的应用范围，并为标靶治疗开闢了新的途径。推动该市场成长的因素包括癌症和心血管疾病等慢性病的盛行率上升，这些疾病需要先进的诊断和治疗解决方案。全球人口老化进一步推动了对核医学的需求，因为老年人更容易患上这些疾病。监管支持和研发投入的增加也是市场扩张的关键驱动因素。此外，个人化医疗的日益普及正在推动核医学的创新，并为精准诊断和治疗创造了机会。在新兴市场，医疗基础设施的改善和公众意识的提高为市场扩张提供了广阔的前景。投资研发和合作的公司能够更好地掌握这些趋势，从而促进核医市场的持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 诊断
    • 治疗
  • 市场规模及预测：依产品划分
    • 放射性药物
    • 核子医学设备
  • 市场规模及预测：依服务划分
    • 放射性同位素的生产
    • 迴旋加速器服务
    • 放射性药物
    • 咨询服务
  • 市场规模及预测：依技术划分
    • PET
    • SPECT
    • 阿尔法发射体
    • β射线放射体
    • 伽玛射线发射体
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 内分泌学
    • 胃肠病学
    • 整形外科
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊断中心
    • 研究所
  • 市场规模及预测：依设备划分
    • PET扫描仪
    • SPECT扫描仪
    • 伽马摄影机
  • 市场规模及预测：依製程划分
    • 影像诊断
    • 治疗方法
  • 市场规模及预测：按模式
    • In vivo
    • 体外
  • 市场规模及预测：依安装类型划分
    • 固定的
    • 移动的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Curium
  • Sofie Biosciences
  • Advanced Accelerator Applications
  • Blue Earth Diagnostics
  • Radiomedix
  • Isologic Innovative Radiopharmaceuticals
  • North Star Medical Radioisotopes
  • Jubilant Radiopharma
  • Shine Medical Technologies
  • Cyclopharm
  • Immunomedics
  • Progenics Pharmaceuticals
  • Lantheus Holdings
  • ITM Isotope Technologies Munich
  • Telix Pharmaceuticals
  • Eckert Ziegler
  • Navidea Biopharmaceuticals
  • Cardinal Health Nuclear Pharmacy Services
  • NTP Radioisotopes
  • BWX Technologies

第九章：关于我们

简介目录
Product Code: GIS32423

Nuclear Medicine Market is anticipated to expand from $17.3 billion in 2024 to $49.4 billion by 2034, growing at a CAGR of approximately 11.8%. The Nuclear Medicine Market encompasses diagnostic and therapeutic applications using radioactive substances. It includes radiopharmaceuticals, imaging devices, and services that leverage nuclear properties for precision medicine. This market is driven by advancements in imaging technologies, increasing prevalence of chronic diseases, and the rising demand for non-invasive diagnostic techniques. Innovations in targeted radionuclide therapy and regulatory approvals are further propelling growth, offering opportunities for enhanced patient outcomes and personalized treatment strategies.

The Nuclear Medicine Market is experiencing robust growth, propelled by advancements in diagnostic imaging and targeted therapeutic techniques. The diagnostic segment is the top performer, primarily driven by the increasing adoption of SPECT and PET imaging technologies. These modalities are essential for precise disease diagnosis and treatment planning. The therapeutic segment follows closely, with radiopharmaceuticals for oncology applications gaining significant traction due to their targeted approach and efficacy. Within the diagnostic sub-segment, PET imaging is expected to maintain its leading position, supported by ongoing technological enhancements and expanding clinical applications. SPECT imaging, as the second-highest performing sub-segment, benefits from its cost-effectiveness and widespread availability. In the therapeutic sub-segment, radiopharmaceuticals targeting prostate cancer and neuroendocrine tumors are anticipated to drive future growth, reflecting advancements in personalized medicine. Additionally, the integration of artificial intelligence in nuclear medicine is poised to enhance diagnostic accuracy and operational efficiency, further fueling market expansion.

Market Segmentation
TypeDiagnostic, Therapeutic
ProductRadiopharmaceuticals, Nuclear Medicine Equipment
ServicesRadioisotope Production, Cyclotron Services, Radiopharmacy, Consultation Services
TechnologyPET, SPECT, Alpha Emitters, Beta Emitters, Gamma Emitters
ApplicationOncology, Cardiology, Neurology, Endocrinology, Gastroenterology, Orthopedics
End UserHospitals, Diagnostic Centers, Research Institutes
DevicePET Scanners, SPECT Scanners, Gamma Cameras
ProcessImaging, Therapy
ModeIn Vivo, In Vitro
Installation TypeFixed, Mobile

The Nuclear Medicine Market is witnessing significant advancements with a diverse range of new product launches enhancing its competitive landscape. Market share is increasingly influenced by pricing strategies and innovative product introductions, which are reshaping consumer preferences and driving demand. As companies focus on enhancing the efficacy and precision of nuclear medicine technologies, the market is poised for substantial growth. Key players are strategically positioning their offerings to capture emerging opportunities, particularly in regions demonstrating heightened healthcare investments. Competition within the nuclear medicine sector is intense, with key players actively benchmarking their offerings against rivals to maintain a competitive edge. Regulatory influences are substantial, with stringent guidelines in North America and Europe shaping operational standards. These regulations, coupled with technological advancements, are pivotal in defining market dynamics. The landscape is characterized by a robust interplay of innovation and compliance, driving market evolution. As regulatory frameworks evolve, they present both challenges and opportunities for market participants seeking to leverage cutting-edge technologies.

Geographical Overview:

The nuclear medicine market is witnessing substantial growth across various regions, each demonstrating unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and significant investments in research and development. The region's emphasis on innovation and early adoption of new technologies further propels market growth. Europe follows suit, with robust healthcare systems and a strong focus on precision medicine enhancing its market potential. The Asia Pacific region is emerging as a lucrative growth pocket, fueled by increasing healthcare expenditure and rising awareness about nuclear medicine's benefits. Countries like China and India are at the forefront, investing heavily in healthcare infrastructure and research initiatives. Latin America, with countries such as Brazil, is also showing promise, driven by improving healthcare access and growing demand for advanced diagnostic techniques. Meanwhile, the Middle East & Africa are gradually recognizing the potential of nuclear medicine, with investments in healthcare modernization and infrastructure development gaining momentum.

The Nuclear Medicine Market faces complex challenges from global tariffs and geopolitical risks, particularly in East Asia. Japan and South Korea are advancing domestic production capabilities to mitigate reliance on imports amid trade tensions. China is enhancing its nuclear medicine infrastructure, focusing on self-sufficiency and innovation to counteract potential supply chain disruptions. Taiwan, with its strategic semiconductor industry, is pivotal yet vulnerable to geopolitical strains. Globally, the nuclear medicine sector is expanding, driven by technological advancements and rising healthcare demands. By 2035, market evolution will hinge on robust regional collaborations and supply chain resilience. Concurrently, Middle East conflicts could escalate energy prices, indirectly affecting production costs and logistics in the nuclear medicine domain, necessitating strategic energy sourcing and risk management.

Key Trends and Drivers:

The nuclear medicine market is experiencing robust growth, propelled by advancements in diagnostic imaging and therapeutic applications. Key trends include the integration of artificial intelligence in imaging technologies, enhancing accuracy and efficiency in disease detection and treatment planning. The development of novel radiopharmaceuticals is expanding the scope of nuclear medicine, offering new avenues for targeted therapies. Drivers of this market include the rising prevalence of chronic diseases such as cancer and cardiovascular disorders, necessitating advanced diagnostic and treatment solutions. The aging global population further fuels demand for nuclear medicine, as older adults are more susceptible to these conditions. Regulatory support and increased funding for research and development are also significant contributors to market expansion. Additionally, the growing adoption of personalized medicine is fostering innovation in nuclear medicine, with opportunities in precision diagnostics and therapeutics. Emerging markets present lucrative opportunities for expansion, driven by increasing healthcare infrastructure and awareness. Companies investing in research and collaborations are well-positioned to capitalize on these trends, ensuring sustained growth in the nuclear medicine market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode
  • 2.10 Key Market Highlights by Installation Type

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostic
    • 4.1.2 Therapeutic
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Radiopharmaceuticals
    • 4.2.2 Nuclear Medicine Equipment
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Radioisotope Production
    • 4.3.2 Cyclotron Services
    • 4.3.3 Radiopharmacy
    • 4.3.4 Consultation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 PET
    • 4.4.2 SPECT
    • 4.4.3 Alpha Emitters
    • 4.4.4 Beta Emitters
    • 4.4.5 Gamma Emitters
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiology
    • 4.5.3 Neurology
    • 4.5.4 Endocrinology
    • 4.5.5 Gastroenterology
    • 4.5.6 Orthopedics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Centers
    • 4.6.3 Research Institutes
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 PET Scanners
    • 4.7.2 SPECT Scanners
    • 4.7.3 Gamma Cameras
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Imaging
    • 4.8.2 Therapy
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 In Vivo
    • 4.9.2 In Vitro
  • 4.10 Market Size & Forecast by Installation Type (2020-2035)
    • 4.10.1 Fixed
    • 4.10.2 Mobile

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
      • 5.2.1.10 Installation Type
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
      • 5.2.2.10 Installation Type
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
      • 5.2.3.10 Installation Type
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
      • 5.3.1.10 Installation Type
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
      • 5.3.2.10 Installation Type
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
      • 5.3.3.10 Installation Type
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
      • 5.4.1.10 Installation Type
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
      • 5.4.2.10 Installation Type
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
      • 5.4.3.10 Installation Type
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
      • 5.4.4.10 Installation Type
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
      • 5.4.5.10 Installation Type
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
      • 5.4.6.10 Installation Type
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
      • 5.4.7.10 Installation Type
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
      • 5.5.1.10 Installation Type
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
      • 5.5.2.10 Installation Type
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
      • 5.5.3.10 Installation Type
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
      • 5.5.4.10 Installation Type
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
      • 5.5.5.10 Installation Type
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
      • 5.5.6.10 Installation Type
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
      • 5.6.1.10 Installation Type
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
      • 5.6.2.10 Installation Type
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
      • 5.6.3.10 Installation Type
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
      • 5.6.4.10 Installation Type
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Mode
      • 5.6.5.10 Installation Type

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Curium
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sofie Biosciences
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Advanced Accelerator Applications
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Blue Earth Diagnostics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Radiomedix
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Isologic Innovative Radiopharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 North Star Medical Radioisotopes
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Jubilant Radiopharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Shine Medical Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cyclopharm
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immunomedics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Progenics Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Lantheus Holdings
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 ITM Isotope Technologies Munich
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Telix Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Eckert Ziegler
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Navidea Biopharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cardinal Health Nuclear Pharmacy Services
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 NTP Radioisotopes
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 BWX Technologies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us